11:07:58 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriBioteknik
Oncopeptides är ett läkemedelsbolag som bedriver forskning och utveckling av cancerläkemedel. Sedan starten fokuserar bolaget främst på den egenutvecklade produkten Ygalo, en alkylerare för behandling av blodbaserade cancersjukdomar. Till kategorin räknas bland annat kronisk leukemi, lymfom och myelom. Bolaget är i utvecklingsfas där målet är att kommersialisera produkten i framtiden. Oncopeptides huvudkontor är beläget i Stockholm.

Kalender

2020-11-19 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning ONCO 0.00 SEK
2020-05-26 Årsstämma 2019
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-12-17 Extra Bolagsstämma 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-05-22 Ordinarie utdelning ONCO 0.00 SEK
2019-05-21 Kvartalsrapport 2019-Q1
2019-05-21 Årsstämma 2018
2019-02-22 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-07-13 Kvartalsrapport 2018-Q2
2018-05-18 Ordinarie utdelning ONCO 0.00 SEK
2018-05-17 Kvartalsrapport 2018-Q1
2018-05-17 Årsstämma 2017
2018-02-22 Bokslutskommuniké 2017
2017-11-15 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-18 Kvartalsrapport 2017-Q1
2017-05-18 Årsstämma 2016
2020-05-26 08:00:00

Summary

Financial overview January 1 - March 31, 2020
  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 297.3 M (loss: 134.1)
  • Loss per share, before and after dilution, was SEK 5.37 (loss: 2.82)
  • On March 31 cash and cash equivalents amounted to SEK 617.8 M (747.5)
Significant events during the period January 1 - March 31, 2020
  • Top line results from the company's pivotal phase 2 study HORIZON were presented and showed a 26% Overall Response Rate (ORR) of melflufen in triple-class refractory multiple myeloma patients
  • The Lancet Haematology published detailed results from Oncopeptides international multi¬center study, O-12-M1
  • Oncopeptides announced that COVID-19 will not affect the company's pivotal studies sig¬nificantly while recruitment to explorative studies and initiating new studies will temporar¬ily be paused
  • The company strengthened its management team with several new senior executives
Significant events after the reporting period
  • In May, Oncopeptides completed a directed share issue of SEK 1,414 million (144 MUSD) before issue costs
  • The enrollment in the pivotal phase 3 study OCEAN was successfully completed in May including 450 patients from more than 100 hospitals around the world

Financial overview of the group

[]
2020 2019[1)] 2019
Jan - Mar Jan - Mar Jan - Dec
Net sales - - -
Operating loss -296,876 -133,812 -739,392
Loss before tax -297,327 -133,946 -739,920
Loss for the period -297,329 -134,077 -740,705
Earnings per share before -5.37 -2.82 -14.33
and after
dilution (SEK)
Cash flow from operating -312,841 -142,821 -690,566
activities
Cash and cash equivalents 617,786 747,471 926,186
at the end of the period
Research & development 72% 80% 74%
costs/operating expenses
%
1) Earlier periods have been adjusted to reflect correction of errors, see note 6.
  

Conference call for investors, analysts and the media
The Interim Report Q1 2020 and an operational update will be presented by CEO Jakob Lindberg and members of Oncopeptides management team, Tuesday May 26, 2020 at 10:00 (CET). The conference call will also be streamed via a link on the website: www.oncopeptides.com.

Phone numbers for participants from:
Sweden: +46 8 505 583 57
Europe: +44 3333 009 271
USA: +1 833 526 83 98

Financial calendar
Annual General Meeting May 26, 2020
Interim Report Q2, 2020: August 26, 2020
Interim Report Q3, 2020: November 19, 2020
 

For further information
Jakob Lindberg, CEO, Oncopeptides AB
E-mail: jakob.lindberg@oncopeptides.com
Telephone: +46 (0)8 615 20 40

Rein Piir, Head of Investor Relations, Oncopeptides AB
E-mail: rein.piir@oncopeptides.com
Telephone: +46 (0)70 853 72 92
 

This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on May 26, 2020.
 

About Oncopeptides
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen (melphalan flufenamide) is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides' headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

For more information please visit www.oncopeptides.com.